Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis.


Journal

American journal of respiratory and critical care medicine
ISSN: 1535-4970
Titre abrégé: Am J Respir Crit Care Med
Pays: United States
ID NLM: 9421642

Informations de publication

Date de publication:
01 04 2019
Historique:
pubmed: 16 10 2018
medline: 21 1 2020
entrez: 16 10 2018
Statut: ppublish

Résumé

High-density lipoprotein (HDL) cholesterol (HDL-C) levels decline during sepsis, and lower levels are associated with worse survival. However, the genetic mechanisms underlying changes in HDL-C during sepsis, and whether the relationship with survival is causative, are largely unknown. We hypothesized that variation in genes involved in HDL metabolism would contribute to changes in HDL-C levels and clinical outcomes during sepsis. We performed targeted resequencing of HDL-related genes in 200 patients admitted to an emergency department with sepsis (Early Infection cohort). We examined the association of genetic variants with HDL-C levels, 28-day survival, 90-day survival, organ dysfunction, and need for vasopressor or ventilatory support. Candidate variants were further assessed in the VASST (Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock Trial) cohort (n = 632) and St. Paul's Hospital Intensive Care Unit 2 (SPHICU2) cohort (n = 203). We identified a rare missense variant in CETP (cholesteryl ester transfer protein gene; rs1800777-A) that was associated with significant reductions in HDL-C levels during sepsis. Carriers of the A allele (n = 10) had decreased survival, more organ failure, and greater need for organ support compared with noncarriers. We replicated this finding in the VASST and SPHICU2 cohorts, in which carriers of rs1800777-A (n = 35 and n = 12, respectively) had significantly reduced 28-day survival. Mendelian randomization was consistent with genetically reduced HDL levels being a causal factor for decreased sepsis survival. Our results identify CETP as a critical regulator of HDL levels and clinical outcomes during sepsis. These data point toward a critical role for HDL in sepsis.

Identifiants

pubmed: 30321485
doi: 10.1164/rccm.201806-1157OC
doi:

Substances chimiques

Cholesterol Ester Transfer Proteins 0
Cholesterol, HDL 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

854-862

Subventions

Organisme : CIHR
ID : 1368896
Pays : Canada

Commentaires et corrections

Type : CommentIn

Auteurs

Mark Trinder (M)

1 Centre for Heart Lung Innovation and.
2 Experimental Medicine Program, University of British Columbia, Vancouver, British Columbia, Canada.

Kelly R Genga (KR)

1 Centre for Heart Lung Innovation and.
2 Experimental Medicine Program, University of British Columbia, Vancouver, British Columbia, Canada.

HyeJin Julia Kong (HJ)

1 Centre for Heart Lung Innovation and.

Lisanne L Blauw (LL)

3 Department of Medicine, Division of Endocrinology and.
4 Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands; and.

Cody Lo (C)

1 Centre for Heart Lung Innovation and.

Xuan Li (X)

1 Centre for Heart Lung Innovation and.

Mihai Cirstea (M)

1 Centre for Heart Lung Innovation and.

Yanan Wang (Y)

3 Department of Medicine, Division of Endocrinology and.
4 Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands; and.

Patrick C N Rensen (PCN)

3 Department of Medicine, Division of Endocrinology and.
4 Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands; and.

James A Russell (JA)

1 Centre for Heart Lung Innovation and.
5 Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Keith R Walley (KR)

1 Centre for Heart Lung Innovation and.
5 Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

John H Boyd (JH)

1 Centre for Heart Lung Innovation and.
2 Experimental Medicine Program, University of British Columbia, Vancouver, British Columbia, Canada.
5 Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Liam R Brunham (LR)

1 Centre for Heart Lung Innovation and.
2 Experimental Medicine Program, University of British Columbia, Vancouver, British Columbia, Canada.
5 Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH